03. Antidepressants in Bipolar: Safer Than Previously Thought? When New Data Challenges Firm Beliefs

Text version

New Meta-Analysis Challenges Standard Recommendations

I’ll admit after first looking at this new article I was confused and concerned. You’ve heard of the standard recommendation. You know: you don’t use antidepressants as monotherapy in bipolar I depression.

But this new network meta-analysis found that no antidepressant was associated with a significantly higher risk of switch to mania relative to placebo. Not even when given as monotherapy.

The 2014 ISBD Task Force Consensus

In 2014, the International Society for Bipolar Disorders (ISBD) convened a task force on antidepressants with 60 co-authors. All the academic bigwigs wanted in on this one.

Their conclusion was that the risk of antidepressants causing a switch into mania is too big. This risk remains high unless the patient is already on an antipsychotic or a mood stabilizer.

The 60 co-authors completed an anonymous, iterative questionnaire series to reach agreement on their final recommendation, the so-called Delphi process. Their firm conclusion for bipolar I was that antidepressant monotherapy can induce mania. Parenthetically, they didn’t comment on the use of antidepressants in bipolar II because the evidence was not sufficient to draw a firm conclusion.

Meta-Analysis Suggests Lower Risk

This new meta-analysis suggests the risk is not large enough to justify that hesitancy. The authors looked only at randomized trials with placebo controls which enabled their network comparison of one antidepressant versus another.

They conclude that “these findings support the cautious use of antidepressants as short-term add-on therapy.” We can take this new network meta-analysis as a reminder that even some of our firmest assumptions could still be held lightly.

We should remain open to rethinking. So let’s dive in asking, what might account for this apparently divergent finding?

Potential Reasons for Divergent Findings

Maybe they defined mania so loosely that many participants experienced it, including those on placebo?

No. They used the definitions in the 13 studies they analyzed. Although the definitions did vary, they used a YMRS of 12 or sometimes 16 or sometimes clinical judgment, but that shouldn’t tilt the data toward their negative finding.

Maybe they only looked at bipolar II and not bipolar I, which is thought to be more prone to switching?

No. 50% had bipolar I and the rest had bipolar II or undifferentiated.

Maybe they only looked at patients also taking a mood stabilizer or antipsychotic, which helps to lower the rate of switching?

No. 30% of the patients were on antidepressant monotherapy.

But those patients came mainly from three trials: two old studies that used amineptine or tranylcypromine and a 2010 study using paroxetine. The latter study set a high bar for calling switch at a YMRS of 16 or more, which is well into the manic range.

So remember, the key conclusion of this new meta-analysis—that antidepressant monotherapy carries a little more risk than a placebo—is strongly based on these three studies.

Venlafaxine Carried Higher Switch Risk

Parenthetically before concluding, an important clinical note: compared to SSRIs, venlafaxine’s relative risk was two to four times higher.

The authors suggested this might be explained by venlafaxine’s noradrenergic effects. Imipramine and desipramine—also noradrenergic—were the next most switch-prone antidepressants.

Bottom Line: Stay Open to Evolving Evidence

So to summarize, this new study reminds us to stay open to data even when they might undermine firm or even cherished beliefs.

Rely on the weight of evidence. Seek consensus but hold conclusions lightly.

Abstract

Switch to mania after acute antidepressant treatment for bipolar depression: a systematic review and network meta-analysis of randomised controlled trials

Vincenzo Olivaa, Michele De Prisco, Enrico La Spina, Sofia Paolucci, Giovanna Fico, Gerard Anmella et al.

Background

The potential for antidepressants to induce a switch to mania remains a major concern in the treatment of bipolar depression, but the specific risk associated with different antidepressants remains unclear. This systematic review and network meta-analysis (NMA) assessed this risk by comparing individual antidepressants with each other and with a common placebo.

Methods

In this systematic review and network meta-analysis, we searched ClinicalTrials.gov, CENTRAL, PsycINFO, PubMed, Scopus, and Web of Science from database inception up to Feb 19, 2025, with no language restrictions, for randomised controlled trials (RCTs) assessing acute antidepressant treatment in bipolar depression. The primary outcome was the rate of switch to mania after antidepressant treatment. A frequentist NMA estimated risk ratios (RRs) and 95% confidence intervals. Sensitivity analyses were performed based on treatment regimen (monotherapy or add-on), baseline severity, switch to mania definition, study setting, psychiatric comorbidity, treatment duration, non-pharmacological combinations, industry sponsorship, and risk of bias. Certainty of evidence was assessed using the CINeMA framework. The protocol was preregistered on the Open Science Framework.

Findings

Of 2434 records screened, 13 RCTs (1362 patients; 818 [60.1%] female, 511 [37.5%] male, and 33 [2.4%] not disclosed) were included in the NMA. Although some evidence of increased risk of switching to mania was observed, no antidepressant was associated with a significantly higher risk of switch to mania compared to placebo. Venlafaxine showed the highest risk estimate among antidepressants, though not statistically significant RR (4.53 [95% CI 0.47–43.25]), and was the only compound with consistent signals of increased switch in individual studies. The evidence base was larger for add-on therapy, while fewer data were available for monotherapy. Sensitivity analyses confirmed the results. Heterogeneity was low. Overall confidence in the evidence was rated as low.

Interpretation

Antidepressants remain a treatment option for acute bipolar depression, particularly as add-on therapy. Their use should be individualised, considering patient-specific profiles and other potential risks, in line with a precision psychiatry approach. Further studies are needed to clarify long-term safety.

Reference

Oliva, V., De Prisco, M., La Spina, E., Paolucci, S., Fico, G. Anmella, G. et al. (2025). Switch to mania after acute antidepressant treatment for bipolar depression: a systematic review and network meta-analysis of randomised controlled trials. eClinicalMedicine; 87